Want to see IN:AJOONI full AI Analyst Report?
Top Page
Ajooni Biotech Limited
(AJOONI)
Select Model
Select Model
Rating:50Neutral
Price Target:
₹3.00
▼(-41.52% Downside)
Action:Reiterated
Date:10/13/26
The score is held back primarily by weak financial quality (multi-year negative operating/free cash flow) and bearish technicals (price below major moving averages with negative MACD). These risks are partially offset by strong recent revenue growth, a still-manageable balance sheet, and a relatively modest P/E valuation.
Positive Factors
Strong Revenue Growth
Accelerating revenue growth indicates improving scale and stronger demand for the company’s animal health and nutrition offerings. Sustained top-line expansion can broaden distribution, support operating leverage, and create a durable base for future earnings growth if execution remains consistent.
Negative Factors
Persistent Negative Cash Generation
Repeated negative operating cash flow means reported earnings have not translated into cash, creating a persistent funding and execution concern. Deeply negative free cash flow can restrict reinvestment, increase reliance on external financing, and weaken the durability of growth unless cash conversion improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Accelerating revenue growth indicates improving scale and stronger demand for the company’s animal health and nutrition offerings. Sustained top-line expansion can broaden distribution, support operating leverage, and create a durable base for future earnings growth if execution remains consistent.
Read all positive factors
Ajooni Biotech Limited (AJOONI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹520.17M
Dividend YieldN/A
Average Volume (3M)296.02K
Price to Earnings (P/E)12.8
Beta (1Y)1.03
Revenue Growth78.39%
EPS Growth15.76%
CountryIN
Employees182
SectorGeneral
Sector StrengthN/A
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.22
Shares Outstanding181,243,590
10 Day Avg. Volume230,426
30 Day Avg. Volume296,019
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)2.02
Price to Sales (P/S)1.01
P/FCF Ratio-7.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ajooni Biotech Limited Business Overview & Revenue Model
Company Description
Founded in 2010, Ajooni Biotech Limited is an Indian enterprise primarily engaged in the production and distribution of animal nutrition products. Headquartered in Mohali, India, the company's offerings encompass specialized cattle feeds and vario...
How the Company Makes Money
Ajooni Biotech Limited primarily makes money by selling animal health and nutrition products (and related livestock/poultry-focused inputs) through its sales and distribution channels to customers in the animal husbandry ecosystem (e.g., farms, di...
Ajooni Biotech Limited Financial Statement Overview
Summary
Income Statement
73
Positive
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.15B | 1.82B | 1.15B | 801.15M | 744.88M | 740.38M |
| Gross Profit | 303.98M | 276.71M | 138.13M | 97.65M | 87.45M | 100.24M |
| EBITDA | 76.80M | 62.56M | 57.57M | 44.27M | 30.60M | 31.12M |
| Net Income | 39.59M | 43.22M | 32.38M | 21.61M | 11.25M | 10.49M |
Balance Sheet | ||||||
| Total Assets | 1.25B | 1.20B | 950.51M | 475.20M | 587.31M | 290.18M |
| Cash, Cash Equivalents and Short-Term Investments | 3.74M | 4.19M | 68.30M | 4.30M | 4.93M | 573.86K |
| Total Debt | 269.11M | 177.63M | 19.40M | 21.68M | 51.77M | 53.50M |
| Total Liabilities | 332.86M | 291.74M | 69.72M | 48.12M | 170.62M | 126.35M |
| Stockholders Equity | 916.23M | 911.91M | 880.79M | 427.08M | 416.69M | 163.82M |
Cash Flow | ||||||
| Free Cash Flow | 18.31M | -232.32M | -192.16M | -95.54M | -84.39M | 15.60M |
| Operating Cash Flow | 135.46M | -52.03M | -171.84M | -39.52M | -55.79M | 36.84M |
| Investing Cash Flow | -122.77M | -170.31M | -171.34M | 76.37M | -158.24M | -18.97M |
| Financing Cash Flow | 71.88M | 158.23M | 248.26M | -35.66M | 216.55M | -19.73M |
Ajooni Biotech Limited Technical Analysis
Negative
5.13
Price Trends
3.29
Negative
3.58
Negative
3.93
Negative
Market Momentum
-0.11
Negative
36.10
Neutral
48.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJOONI, the sentiment is Negative. The current price of 5.13 is above the 20-day moving average (MA) of 2.98, above the 50-day MA of 3.29, and above the 200-day MA of 3.93, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 36.10 is Neutral, neither overbought nor oversold. The STOCH value of 48.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:AJOONI.
Ajooni Biotech Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹89.82B | 16.46 | ― | 1.52% | 11.35% | -8.27% | |
64 Neutral | ₹29.22B | 22.12 | ― | 0.47% | 10.91% | 3.74% | |
60 Neutral | ₹10.24B | 9.76 | ― | 0.64% | 21.31% | 89.98% | |
56 Neutral | ₹7.38B | 10.55 | ― | ― | 76.01% | 59.13% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹520.17M | 12.76 | ― | ― | 78.39% | 15.76% | |
47 Neutral | ₹1.48B | 29.54 | ― | ― | 17.76% | -50.16% |
* General Sector Average
IN:AJOONI
Ajooni Biotech Limited
2.87
-2.30
-44.49%
IN:AVANTIFEED
Avanti Feeds Limited
659.25
-30.43
-4.41%
IN:MKPL
M K Proteins Limited
3.93
-2.88
-42.29%
IN:MUKKA
Mukka Proteins Limited
24.60
-0.59
-2.34%
IN:PARAGMILK
Parag Milk Foods Ltd.
232.80
-77.74
-25.03%
IN:SKMEGGPROD
SKM Egg Products Export (India) Ltd.
194.50
-13.59
-6.53%
Ajooni Biotech Limited Corporate Events
Ajooni Biotech Confirms SEBI-Compliant Corporate Website Now Fully Functional
Oct 19, 2026
Ajooni Biotech Limited has notified the National Stock Exchange of India that its corporate website has been updated and is now fully functional in line with Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.